These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 827037)

  • 21. The effect of an immune RNA (RNAi) against Trypanosoma cruzi infection in mice.
    Lemos MV; Menezes H
    Tropenmed Parasitol; 1978 Mar; 29(1):119-26. PubMed ID: 417440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
    Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
    Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trypanosoma cruzi and immunoprotection: study of an attenuated strain.
    de Campanini AR; Esteva M; Laguens RP; Segura EL
    Medicina (B Aires); 1982; 42(5):502-6. PubMed ID: 6820463
    [No Abstract]   [Full Text] [Related]  

  • 24. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.
    Krettli AU; Brener Z
    J Immunol; 1982 May; 128(5):2009-12. PubMed ID: 6801127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation between Trypanosoma cruzi and T. rangeli by their different complement sensitivity.
    Schottelius J
    Tropenmed Parasitol; 1982 Sep; 33(3):147-50. PubMed ID: 6814023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trypanosoma rangeli: epimastigote immunogenicity and cross-reaction with Trypanosoma cruzi.
    Saldaña A; Sousa OE
    J Parasitol; 1996 Apr; 82(2):363-6. PubMed ID: 8604121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superinfections with genetically characterized Trypanosoma cruzi clones did not aggravate morbidity and mortality in BALB/c mice.
    Lauria-Pires L; Teixeira AR
    J Parasitol; 1997 Oct; 83(5):819-24. PubMed ID: 9379284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
    Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
    Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of inbred mice to Trypanosoma cruzi strain Y.
    Corsini AC; Costa MG; Oliveira OL; Camargo IJ; Stelini A
    Rev Inst Med Trop Sao Paulo; 1980; 22(4):192-6. PubMed ID: 6782638
    [No Abstract]   [Full Text] [Related]  

  • 30. Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.
    Giddings OK; Eickhoff CS; Smith TJ; Bryant LA; Hoft DF
    Infect Immun; 2006 Oct; 74(10):5549-60. PubMed ID: 16988230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanosoma cruzi triggers an early type I IFN response in vivo at the site of intradermal infection.
    Chessler AD; Unnikrishnan M; Bei AK; Daily JP; Burleigh BA
    J Immunol; 2009 Feb; 182(4):2288-96. PubMed ID: 19201883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crossed-immunoelectrophoretic analyses of Trypanosoma cruzi epimastigote, metacyclic, and bloodstream forms.
    Okanla EO; Stumpf JL; Dusanic DG
    J Parasitol; 1982 Aug; 68(4):538-46. PubMed ID: 6750069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of congenitally athymic mice against Trypanosoma cruzi infection by passive antibody transfer.
    Kierszenbaum F
    J Parasitol; 1980 Aug; 66(4):673-5. PubMed ID: 6775071
    [No Abstract]   [Full Text] [Related]  

  • 34. Passive protection of mice against infection with Trypanosoma cruzi with plasma: the use of blood- and vector bug-derived trypomastigote challenge.
    McHardy N
    Parasitology; 1980 Jun; 80(3):471-8. PubMed ID: 6771737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological characterization of Trypanosoma cruzi stocks from Chilean insect vectors.
    Solari A; Wallace A; Ortiz S; Venegas J; Sanchez G
    Exp Parasitol; 1998 Jul; 89(3):312-22. PubMed ID: 9676709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
    Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
    Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trypanosoma cruzi: protection of mice with epimastigote antigens from immunologically different parasite strains.
    González Cappa SM; Pesce UJ; Cantarella AI; Schmuñis GA
    Exp Parasitol; 1974 Apr; 35(2):179-86. PubMed ID: 4206928
    [No Abstract]   [Full Text] [Related]  

  • 38. Side effects of immunization with liver attenuated Trypanosoma cruzi in mice and rabbits.
    Basombrío MA; Besuschio S; Cossio PM
    Infect Immun; 1982 Apr; 36(1):342-50. PubMed ID: 6804389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of macrophages in the genetic control of the susceptibility and resistance to experimental infection by Trypanosoma cruzi (proceedings)].
    Pécora IL; Barcinski MA; Gaspar MI
    An Acad Bras Cienc; 1978 Sep; 50(3):430. PubMed ID: 103472
    [No Abstract]   [Full Text] [Related]  

  • 40. Enzymes of the antioxidant network as novel determiners of Trypanosoma cruzi virulence.
    Piacenza L; Zago MP; Peluffo G; Alvarez MN; Basombrio MA; Radi R
    Int J Parasitol; 2009 Nov; 39(13):1455-64. PubMed ID: 19505468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.